The Role of Insulin-Like Growth Factor I Components in the Regulation of Vitamin D
Author: Manuel Gomez, Jose
Source: Current Pharmaceutical Biotechnology, Volume 7, Number 2, April 2006 , pp. 125-132(8)
Publisher: Bentham Science Publishers
Abstract:
Several factors are known to be involved in the regulation of vitamin D and sunlight and diet are the two sources in humans, but the relative importance of each of them is not well defined. Vitamin D, parathyroid hormone and serum insulin-like growth factor-I (IGF-I) were found to be independent predictors of total bone density. Thus, the growth hormone (GH)/IGF-I is thought to play an important role in the regulation of bone mineral density and the skeleton is second only to the liver as a source of circulating levels of IGF-I. The mechanisms by which IGF-I may influence bone metabolism is not fully understood but they are a predictor of bone mass density and are positively associated with vitamin D concentrations. There is a physiological decline of the GH/IGF axis with ageing. The high affinity IGFbinding proteins (IGFBP-1 to 6) have also been involved in IGF-I regulation, and it is important to include the IGFindependent properties, particularly those of IGFBP3 that may be involved in the osteoblastic differentiation observed in human bone marrow stromal cell cultures. These hormones have been shown to up regulate each other. 1,25-(OH) D3 has been shown to promote the action of IGF-I by increasing IGF-I receptors and IGF-I can also elevate 1,25-(OH) D3 concentrations by stimulating the hydroxylation of 25-(OH) D3 in the active 1,25-(OH) D3 hormone. Both GH and IGF-I significantly increased renal 1a-hydroxylase expression and serum 1, 25-(OH) D3 concentrations. In prostate cells, 1,25-(OH) D3 is growth inhibitory for many established cell lines and the role of IGFBPs, especially IGFBP-3, can be growth inhibitory or stimulatory and IGFBP-3 expression increases in response to 1,25-(OH) D3, or its analogs, in established prostate cancer cell lines. Body fat is inversely associated with 25-(OH) D3 in relation to with anthropometric measures, indicating a specific role of adipose tissue. IGF-I may be involved in both normal and abnormal fetal growth and stimulation of IGF-I synthesis during normal pregnancy may be associated with an increase in GH production by the placenta. Thus, maternal and umbilical cord serum IGF-I and 1,25-(OH) D3 concentrations are lower in preeclampsia and umbilical cord serum IGF-I, IGFBP-1 and IGFBP-3 concentrations are associated with low newborn birth weights.Keywords: 1,25-(OH) D3; 25-(OH) D3; anthropometry; body composition; free IGF-I; IGF-I; IGFBP3; vitamin D
Document Type: Research article
DOI: http://dx.doi.org/10.2174/138920106776597621
Affiliations: 1: Sabino de Arana 40, 3º,2ª, Barcelona 08028. Spain.
Publication date: 2006-04-01
- Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
- In this: publication
- By this: publisher
- In this Subject: Nutrition & Food , Biotechnology , Pharmacology
- By this author: Manuel Gomez, Jose

Shopping cart
Receive new issue alert
Get Permissions